GlassScriptPhysician profile
Tami Berckenhoff
NPI 1801955893
$9,719.57
in general payments reported to CMS, 2019-2025
47 companies · $1,745 in 2025
The $1,745 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,692 · 2022: $1,830 · 2023: $1,886 · 2024: $1,566 · 2025: $1,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,197.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,343.62 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,231.17 | 2021 | |
| Novo Nordisk INC | $1,194.23 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $691.35 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $493.35 | 2021-2025 | Otezla, Repatha, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $477.13 | 2022-2025 | |
| Pfizer INC. | $440.36 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $308.72 | 2021-2025 | Cycloset, Xifaxan |
| Astrazeneca Pharmaceuticals LP | $294.10 | 2021-2025 | Farxiga, Airsupra, Fasenra |
| Otsuka America Pharmaceutical, INC. | $243.65 | 2021-2024 | Rexulti |
| Bausch Health US, LLC | $237.52 | 2021-2025 | Aplenzin |
| Biohaven Pharmaceutical Holding Company LTD. | $209.71 | 2022 | |
| Radius Health, INC. | $183.53 | 2021-2025 | Tymlos |
| Takeda Pharmaceuticals U.S.A., INC. | $183.53 | 2021-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $146.37 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.63 | 2021-2025 | Jardiance |
| Abbott Laboratories | $133.29 | 2021-2024 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $131.28 | 2021-2025 | Licart, Tirosint, Flector |
| Esperion Therapeutics, INC. | $128.19 | 2021-2025 | Nexletol |
| Exact Sciences Corporation | $119.27 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $118.56 | 2023-2025 | Rexulti, Vyepti |
| Glaxosmithkline, LLC. | $99.43 | 2022-2023 | Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $98.04 | 2021-2023 | |
| Antares Pharma, INC. | $93.23 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Dexcom, INC. | $83.68 | 2022-2023 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $77.99 | 2022-2023 | Quviviq |
| Amarin Pharma, INC. | $75.00 | 2021 | |
| Currax Pharmaceuticals LLC | $73.76 | 2023-2024 | Contrave, Nexletol, Nexlizet |
| Tolmar, INC. | $73.02 | 2023-2025 | Jatenzo |
| Hologic Sales and Service, LLC | $63.48 | 2025 | Thinprep 2000 Processor |
| Ascensia Diabetes Care US INC. | $59.64 | 2025 | |
| Acella Pharmaceuticals, LLC | $56.53 | 2024-2025 | NP Thyroid 60 |
| Madrigal Pharmaceuticals | $45.83 | 2025 | Rezdiffra |
| Novartis Pharmaceuticals Corporation | $43.50 | 2021-2022 | |
| Medtronic, INC. | $39.76 | 2025 | Inceptiv |
| Horizon Therapeutics Plc | $39.73 | 2022-2023 | Tepezza |
| Clarus Therapeutics INC. | $32.43 | 2021 | |
| Mannkind Corporation | $31.67 | 2021 | |
| Acerus Pharmaceuticals Corporation | $26.72 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.17 | 2022 | |
| Halozyme INC | $23.47 | 2023 | |
| Millicent US INC | $22.26 | 2024 | Intrarosa, Femring |
| Xeris Pharmaceuticals, INC. | $20.08 | 2025 | Gvoke Hypopen |
| Genentech USA, INC. | $17.11 | 2021 | |
| Scynexis, INC. | $16.86 | 2022 | |
| Sumitomo Pharma America, INC. | $16.61 | 2024 | Gemtesa |
| Tandem Diabetes Care, INC. | $16.01 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tami Berckenhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.